drugset
Drugs / BYON4228
last change May 2026 re-read 3 minutes ago

BYON4228

Monoclonal antibody targets SIRPA via inhibition

Developed for
cancer · lymphoma
Investigated by
Byondis B.V.

Trials 2

today NCT06932952 · Ph 1 NCT05737628 · Ph 1
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06932952 May 2025 → Apr 2026 overdue cancer Byondis B.V. Active not recruiting No outcome recorded
Phase 1 NCT05737628 Mar 2024 → Feb 2026 overdue lymphoma Byondis B.V. Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-04-17 Byondis B.V. Results Preclinical Characterization of Anti-SIRPα mAb BYON4228 Published in Journal for ImmunoTherapy of Cancer byondis.com ↗

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BYON4228 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737628 ↗
1

NCT06932952 ↗
Action Inhibit “BYON4228 blocks binding of SIRPα to CD47 and inhibits signaling through the CD47-SIRPα axis.” NCT05737628 ↗
Modality Monoclonal antibody “BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα” NCT05737628 ↗
Route Intravenous “BYON4228 IV infusion every four weeks” NCT05737628 ↗
Target SIRPA “BYON4228 is a humanized IgG1 mAb directed against SIRPα.” NCT06932952 ↗